Company Terminal

Insilico Medicine

Insilico Medicine is a clinical-stage AI-driven drug discovery company that develops Pharma.AI, an end-to-end generative AI platform spanning target discovery (PandaOmics), de novo molecular design (Chemistry42), and clinical-trial outcome prediction (InClinico). The company also runs an internal pipeline of drug candidates advanced using its own platform.

Momentum
Not scored
as of 2026-08-03
Funding
—
Founded
—
Stack
—
Research Tier A
0%
needs citations
Momentum inputsNot scored · need ≥2 signals · as of 2026-08-03

No momentum signals yet for this company. See docs/MOMENTUM.md.

No radar series.

Linked model value

    No headcount (est.) series yet.
    No capital raised (est.) series yet.
    No monthly web attention (est.) series yet.
    No geographic reach (countries, est.) series yet.

    Research completeness

    • Tier A: 0% (0/0)
    • Tier B: 0% · Tier C: 0%
    • Publish gate: Blocked
    Open in Research Desk →

    Citations / claims

    No claims yet. Run seed_provenance_tier_a.sql or add sources in Research Desk.

    What they do

    Who is this for? Teams evaluating AI vendors in this category.

    Why different? Insilico Medicine is a clinical-stage AI-driven drug discovery company that develops Pharma.AI, an end-to-end generative AI platform spanning target discovery (PandaOmics), de novo molecular design (Chemistry42), and clinical-trial outcome prediction (InClinico). The company also runs an internal pipeline of drug candidates advanced using its own platform.

    Models & technologies

    No owned model versions linked yet.

    Competitors

    Provenance

    Profile loaded from supabase. Claims and metric observations carry confidence labels; prefer primary URLs in Research Desk over estimate backfills.